Wilson Therapeutics to host conference call to provide fourth quarter 2017 business update

On February 21, 2018, at 07:00 CET, Wilson Therapeutics will publish its year-end report for 2017. All interested parties are invited to participate in a web-cast telephone conference at 10:00 CET, on the same day. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf and will include a presentation in English.

How to participate

The live webcast and a recorded on-demand version including the presentation material will be accessible at:
https://tv.streamfabriken.com/wilson-therapeutics-q4-2017. Questions can be asked in writing via the webcast or verbally via the conference call.

To participate in the conference call, please call one of the following numbers:

  • SE: +46 8 566 426 69
  • UK: +44 203 008 9817
  • US: +1 855 831 5944

The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com, under Media & Investors/Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.
    

For further information please contact:

Lauren Williams, Head of Investor Relations, Wilson Therapeutics AB
Phone:     +44 7958 669 896
E-mail:    lauren.williams@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm

The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on February 14, 2018.

Tags:

About Us

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Subscribe

Documents & Links